SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CRINGE is a Solana meme token centered around all images, videos, and actions which are cringe!  Warning: Cringe Alert! Remember, folks! Just like we don't judge people based on race, ethnicity, or color, we shouldn't judge them for being cringe. After all, cringe isn't ugly - it's just... special. 😉  Embrace your inner cringe, because in a world full of copycats, being cringey is the new cool!  Meme coins are driven by community, and our community is CRINGE as heck!

CRINGE

CRINGE is generating intense debate as traders weigh the risks of high-volatility microcap pump-and-dump cycles against the potential for rapid gains. The community remains deeply divided, with some actively promoting new tokens while others warn of the dangers posed by aggressive price swings and bot activity.

meme + coin =

Community members are actively promoting the MOIN meme coin, focusing on social-driven accumulation and collective efforts to reach specific market capitalization milestones. While proponents highlight technical structures and clean price action, skeptics remain wary of potential volatility and the risks associated with early-stage speculative assets.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around a significant milestone with over 21% of the total token supply locked on-chain. Supporters are actively promoting a long-term 'hopecore' narrative, leveraging viral short-form video content to build momentum ahead of the project's upcoming one-year anniversary.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is generating significant community discourse as traders debate its potential for long-term value against a backdrop of broader crypto volatility and speculative memecoin activity. While some participants are capitalizing on staking opportunities and ecosystem development, others are expressing caution due to market sensitivity to macroeconomic headlines and the high-risk nature of the current trading environment.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point of debate as investors weigh significant structural changes, including a board restructuring and workforce reductions, against its ongoing struggle to break out of historical price lows. While some in the community highlight the network's high transaction volume and institutional pivot as long-term bullish catalysts, others remain deeply skeptical and vocal about the persistent downward pressure on the token.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

Investors are actively accumulating shares of the NEOS Nasdaq 100 High Income ETF, driven by its double-digit monthly yield and a strategy that provides Nasdaq-100 exposure with a buffer during market pullbacks. The community is heavily focused on long-term wealth building, with many using the fund as a tax-efficient, passive income generator to fund early retirement goals.

What makes MOG an absolute game-changer is our relentless dedication to memes and viral brilliance! We don't settle for mediocrity; we plunge into the realm of sheer awesomeness! Our community is a powerhouse of meme warriors, unleashing an unstoppable onslaught of viral memes that'll leave you in awe and stitches!  We're not here to play games; we're here to dominate! MOG is all about pushing the boundaries, smashing through barriers, and leaving our competitors eating our dust! Our passion for humor burns like an inferno, and we won't rest until the entire internet bows down to our meme supremacy!  And our community? It's a brotherhood, an unyielding powerhouse of support and camaraderie! When you're part of MOG, you're part of an unstoppable force, a family forged by the fire of meme revolution!  So, if you're ready to be part of the most intense, mind-bending memecoin movement ever conceived, then buckle up, strap in, and brace yourself! MOG is here to claim the throne, and we're taking no prisoners! Get ready to witness meme history in the making!

 MOG Coin

MOG coin is facing significant scrutiny from the community, with many users labeling it a "scam" and urging others to sell amidst concerns over its recent price performance and lack of utility. Despite the negativity, a dedicated group of followers remains bullish, framing current dips as accumulation opportunities ahead of a potential broader altcoin cycle.

iShares Trust - iShares Russell 2000 Value ETF

iShares Russell 2000 Value ETF

The iShares Russell 2000 Value ETF is currently drawing investor attention as market participants debate whether small-cap valuations remain attractive or reflect broader economic risks amid policy uncertainty. Community discussions are heavily focused on the potential for a rotation into value-oriented small-caps, with many traders analyzing how recent interest rate narratives and economic indicators are impacting sector leadership.

Expand Energy Corp. engages in the production and development of natural gas, oil, and natural gas liquids. Its operations include Haynesville, Northeast Appalachia, and Southwest Appalachia. The company was founded in 2024 and is headquartered in Oklahoma City, OK.

Expand Energy Corp. - Ordinary Shares - New

Chesapeake Energy Corp

Chesapeake Energy is trending as investors monitor its pending merger with Southwestern Energy, which is set to create a major U.S. natural gas producer. The community is actively debating the deal's valuation, potential production strategies, and the stock's long-term outlook amid broader volatility in the natural gas market.

iShares Trust - iShares U.S. Oil & Gas Exploration & Production ETF

BlackRock Institutional Trust Company N.A. - iShares U.S. Oil & Gas Exploration & Production ETF

The IEO ETF is drawing attention as market participants debate the timing of energy sector rotation and the potential for a rebound in domestic oil and gas production. Traders are actively discussing technical support levels, the impact of broader energy price trends, and contrasting bullish outlooks from analysts against sector-wide concerns about profitability and environmental regulations.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiologys 75th Annual Scientific Session and Expo

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its...

<ul class="summary-bullets"><li>Wave said earlier on Thursday that individuals administered a single 240 mg dose of WVE-007 showed a body weight reduction of 0.9% in the early stage portion of its trial.</li><li>Jones Research attributed WVE’s selloff on Thursday to the low total weight loss at six months, 0.9% versus hopes for 2% or 3%.</li><li>Unlike traditional GLP-1 drugs that often lead to muscle loss, Arrowhead’s obesity candidates, ARO-INHBE and ARO-ALK7, aim to reduce body fat, while specifically preserving lean muscle mass.</li></ul> Shares of Arrowhead Pharmaceuticals Inc. (ARWR) fell nearly 2% on Thursday before paring back losses after Wave Life Sciences (WVE) announced mixed data from the early stage portion of its trial evaluating its investigational drug WVE-007 in individuals with obesity.Leerink analyst Mani Foroohar said that they are not surprised to see ARWR stock down as material obesity value is baked in at Arrowhead’s $8.5 billion market cap. The firm has a ‘Market Perform’ rating on Arrowhead shares.Wave said earlier on Thursday that individuals administered a single 240 mg dose of WVE-007 showed a body weight reduction of 0.9% in the early stage portion of the trial, with clinically meaningful reductions in visceral fat and waist circumference, after six months. The investigational drug was well tolerated to date up to 600 mg with no treatment discontinuations, the company said.<a href="https://stocktwits.com/symbol/WVE">WVE shares</a> traded 50% lower at the time of writing. &nbsp;<h2 class="st-heading-2">Why The WVE Selloff?</h2>Jones Research attributed WVE’s selloff to the low total weight loss at six months, 0.9% versus hopes for 2% or 3%. The firm believes that while WVE-007 may not be competitive to GLP-1 category weight loss drugs in the general population, there is still a chance for utility in the elderly or patients with metabolic disease.Jones Research has a ‘Buy’ rating on Wave Life with a $35 price target.Leerink analyst Joseph Schwartz, meanwhile, said that the firm likes the continued improvement in visceral fat reduction at 240 mg after six months, as well as the larger reduction on waist circumference and measurable body weight reduction. The stock's reaction premarket seems to remove all value for WVE-007, which is "very overdone," the firm said. Leerink has an ‘Outperform’ rating on WVE shares.<h2 class="st-heading-2">Arrowhead’s Obesity Pipeline</h2>Unlike traditional GLP-1 drugs that often lead to muscle loss, Arrowhead’s obesity candidates, ARO-INHBE and ARO-ALK7, aim to reduce body fat while specifically preserving lean muscle mass.While comparisons between Wave and Arrowhead data are impaired by small numbers of patients, differences in baseline, and other factors, the greater than 50% fall in Wave's stock price "highlights the degree of optimism baked into INHBE expectations" and brings questions related to Arrowhead "back to center stage," Foroohar told investors, as per TheFly.BofA, meanwhile, lowered the firm's price target on Arrowhead to $81 from $84 and kept a ‘Buy’ rating on the shares. The analyst said that Wave’s update appears largely priced in.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ARWR stock improved from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/ARWR">ARWR stock</a> has more than quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/htz-stock-soars-tsa-delays-airports-spike-in-car-rental-searches/cZ3sTFCRIke">HTZ Stock Soars After TSA Delays At Airports Reportedly Result In Spike In Car Rental Searches</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen.

ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It?

Leerink analyst Mani Foroohar said that they are not surprised to see Arrowhead Pharmaceuticals’ stock down as material obesity value is baked in at the company’s $8.5 billion market cap.

Equity

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down   - What's Next?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down - Here's What Happened...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.6% - Here's What Happened

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 8.6% - Time to Buy...

Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Nordea Investment Management AB

Nordea Investment Management AB lowered its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 12.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 324,251 shares of the biotechnology comp...

Assenagon Asset Management S.A. Purchases 304,264 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Assenagon Asset Management S.A. raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 79.9% during the fourth quarter, according to the company in its most recent...

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning Anti-Aging Protein Research Takes a Step Forward with Cell Cloning PR Newswire VANCOUVER, BC, March 24, 2026 Issued on behalf of Ava...

JPMorgan Chase & Co. Grows Stake in Arrowhead Pharmaceuticals, Inc. $ARWR

JPMorgan Chase & Co. grew its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 90.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 775,717 shares of the biotechnology company's stock after buying an additional 3...

Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP reduced its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 65.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 90,000 shares of the biotechnology company's st...

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

ARWR
Arrowhead Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARWR News

ARWRArrowhead Pharmaceuticals Inc.